Form 4: Ocular Therapeutix Director Granted Equity Awards, Updates Beneficial Ownership

Richard L. Lindstrom, M.D., a Director at Ocular Therapeutix, Inc., was granted 14,000 Restricted Stock Units and 44,000 stock options, while also clarifying his beneficial ownership of common stock.

Summary

• Richard L. Lindstrom, M.D., a Director of Ocular Therapeutix, Inc. (OCUL), was granted 14,000 Restricted Stock Units (RSUs) on June 11, 2025, under the company's 2021 Stock Incentive Plan.
• Each RSU represents a right to receive one share of the company's common stock, with vesting contingent on continued service and occurring 100% on the first anniversary of the grant date or prior to the next annual meeting of stockholders.
• Dr. Lindstrom was also granted 44,000 stock options on June 11, 2025, with an exercise price of $8.82 per share and an expiration date of June 10, 2035.
• These stock options will vest 100% on the first anniversary of the grant date or prior to the next annual meeting of stockholders, subject to Dr. Lindstrom's continued service on the board.
• Following these transactions, Dr. Lindstrom directly beneficially owns 143,145 shares of common stock and 44,000 stock options.
• The filing also corrected a previous reporting error, clarifying that 43,559 shares were indirectly owned by the Lindstrom Family No 2 Limited Partnership, rather than directly owned by Dr. Lindstrom.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a director receiving equity compensation, which aligns their interests with the company's performance and suggests continued commitment. It's a routine transaction, not indicative of major positive or negative news.

Positives

• The grant of RSUs and stock options to a director indicates continued alignment of management's interests with shareholder value, as the awards vest based on continued service and potential stock price appreciation.
• The acquisition of additional equity by a director can be viewed as a sign of confidence in the company's future prospects.

Risks

• The vesting of both the Restricted Stock Units and stock options is subject to the reporting person's continued service on the Company's board of directors, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The equity grants are forward-looking, with vesting contingent on the director's continued service on the board until the first anniversary of the grant date or the next annual meeting of stockholders, whichever is earlier. This aligns the director's future incentives with the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically equity compensation grants to a director. Such grants are common practice across industries to incentivize and retain key personnel, aligning their interests with long-term shareholder value. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The filing corrected a previous error, clarifying that 43,559 shares of common stock are indirectly owned by the Lindstrom Family No 2 Limited Partnership, which is a related party to the reporting person.

Stakeholder Impact

• Shareholders: The grant of equity awards to a director can be seen as a positive signal, aligning the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price appreciates.
• Employees: No direct impact on employees is indicated by this specific filing, though the underlying stock incentive plan is a broader employee/director compensation framework.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on the first anniversary of the grant date (June 11, 2025) or immediately prior to the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Insider Transaction, Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, SEC Filing